186 related articles for article (PubMed ID: 38724462)
1. Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy.
Lischer C; Eberhardt M; Flamann C; Berges J; Güse E; Wessely A; Weich A; Retzlaff J; Dörrie J; Schaft N; Wiesinger M; März J; Schuler-Thurner B; Knorr H; Gupta S; Singh KP; Schuler G; Heppt MV; Koch EAT; van Kleef ND; Freen-van Heeren JJ; Turksma AW; Wolkenhauer O; Hohberger B; Berking C; Bruns H; Vera J
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724462
[TBL] [Abstract][Full Text] [Related]
2. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
3. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
[TBL] [Abstract][Full Text] [Related]
4. Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse.
Charneau J; Suzuki T; Shimomura M; Fujinami N; Mishima Y; Hiranuka K; Watanabe N; Yamada T; Nakamura N; Nakatsura T
Cancer Sci; 2022 Apr; 113(4):1113-1124. PubMed ID: 35122353
[TBL] [Abstract][Full Text] [Related]
5. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775115
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
[TBL] [Abstract][Full Text] [Related]
7. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
8. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.
Feola S; Chiaro J; Martins B; Russo S; Fusciello M; Ylösmäki E; Bonini C; Ruggiero E; Hamdan F; Feodoroff M; Antignani G; Viitala T; Pesonen S; Grönholm M; Branca RMM; Lehtiö J; Cerullo V
Elife; 2022 Mar; 11():. PubMed ID: 35314027
[TBL] [Abstract][Full Text] [Related]
9. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
10. Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.
Nelde A; Maringer Y; Bilich T; Salih HR; Roerden M; Heitmann JS; Marcu A; Bauer J; Neidert MC; Denzlinger C; Illerhaus G; Aulitzky WE; Rammensee HG; Walz JS
Front Immunol; 2021; 12():705974. PubMed ID: 34305947
[TBL] [Abstract][Full Text] [Related]
11. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
[TBL] [Abstract][Full Text] [Related]
12. Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis.
Carter JA; Matta B; Battaglia J; Somerville C; Harris BD; LaPan M; Atwal GS; Barnes BJ
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38135347
[TBL] [Abstract][Full Text] [Related]
13. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
14. MMP-7 derived peptides with MHC class-I binding motifs from canine mammary tumor tissue elicit strong antigen-specific T-cell responses in BALB/c mice.
Yadav PK; Gupta SK; Kumar S; Ghosh M; Yadav BS; Kumar D; Kumar A; Saini M; Kataria M
Mol Cell Biochem; 2021 Jan; 476(1):311-320. PubMed ID: 32970284
[TBL] [Abstract][Full Text] [Related]
15. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
16. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
Bullock TN; Mullins DW; Colella TA; Engelhard VH
J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
[TBL] [Abstract][Full Text] [Related]
17. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).
Koumantou D; Barnea E; Martin-Esteban A; Maben Z; Papakyriakou A; Mpakali A; Kokkala P; Pratsinis H; Georgiadis D; Stern LJ; Admon A; Stratikos E
Cancer Immunol Immunother; 2019 Aug; 68(8):1245-1261. PubMed ID: 31222486
[TBL] [Abstract][Full Text] [Related]
18. New cancer therapy by immunomanipulation: development of immunotherapy for human melanoma as a model system.
Kawakami Y
Cornea; 2000 May; 19(3 Suppl):S2-6. PubMed ID: 10832714
[TBL] [Abstract][Full Text] [Related]
19.
Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
[TBL] [Abstract][Full Text] [Related]
20. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
Murata K; Nakatsugawa M; Rahman MA; Nguyen LT; Millar DG; Mulder DT; Sugata K; Saijo H; Matsunaga Y; Kagoya Y; Guo T; Anczurowski M; Wang CH; Burt BD; Ly D; Saso K; Easson A; Goldstein DP; Reedijk M; Ghazarian D; Pugh TJ; Butler MO; Mak TW; Ohashi PS; Hirano N
Elife; 2020 Apr; 9():. PubMed ID: 32314731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
